Healthcare Professionals

Committed to helping you meet the evolving challenges and opportunities in patient care.

Healthcare Professionals
  • Primary Care

    Supporting every aspect of your clinical practice, including physical exam, diagnostic cardiology, vitals monitoring and vision screening

  • Hospital Care

    Advancing products and technologies designed to speed patient recovery and streamline clinical workflows

  • Surgical Care

    Delivering innovations that enable reduced operating times, faster patient recovery and improved outcomes

  • Kidney Care

    Pioneering care in hemodialysis (HD), peritoneal dialysis (PD) and digital health to support better outcomes for your patients

  • Nutritional Care

    Personalizing nutritional care designed to improve patients’ health in the hospital, the ICU and at home

  • Respiratory Care

    Helping your patients with respiratory therapies designed to simplify delivery and improve mobility

  • Our Products & Services

    Our portfolio of acute, nutritional, renal, hospital and surgical care products helps advance healthcare around the world.

Perspectives

For nearly a century, we have worked at the intersection of saving and sustaining lives.

Perspectives

Our Story

Our 90-year heritage gives us distinct perspective on the needs of patients and caregivers. We lead today by putting those insights to work to deliver new, better healthcare solutions and access to care in the communities where we live and work.

Our Story
  • Our Leadership

    Our forward-looking leadership team is a driving force in ensuring we meet the needs of all our stakeholders – every day and everywhere.

  • Our Governance

    We are proud of our strong commitment to maintaining the highest standards of corporate governance.

  • Fueling Collaborative Innovation

    Nurturing a culture of innovation is critical to delivering on our mission to save and sustain lives. We partner with the healthcare community to continually find more efficient, smarter ways to help solve the world's most pressing healthcare challenges.

  • Corporate Responsibility

    We strive to create lasting value by empowering our patients, protecting our planet and championing our people and communities.

  • Diversity, Equity & Inclusion

    We are committed to attracting, motivating and retaining an inclusive and diverse workforce.

  • Our History

    For nearly a century, we’ve been focused on saving and sustaining lives and elevating patient care.

Patients

Helping you reach a healthy life, full of possibility.

Patients
  • General Healthcare

    Whether you are receiving care in the hospital, at your doctor’s office or at home, we are here to support every step of your journey.

  • Nutritional Care

    When medical conditions prevent you from adequately feeding yourself, we provide life-saving clinical nutrition options to help you regain your nutritional status.

  • Kidney Care

    Kidney disease is an ongoing journey for you and your family. While every journey is unique, Baxter is committed to supporting access to care options to meet your medical and lifestyle needs.

  • Respiratory Care

    We are committed to helping you with innovative products that deliver effective, proven respiratory therapy in the hospital and at home.

Baxter Announces U.S. FDA Clearance of ST Set Used to Help Treat Acute Kidney Injury Patients in the Hospital

Press Release

  • ST Set previously obtained FDA Emergency Use Authorization (EUA) to help meet increased demand for continuous renal replacement therapy (CRRT) products during the COVID-19 pandemic

  • Offers additional option to provide CRRT for patients in an acute care environment  

PDF

DEERFIELD, Ill. -

Baxter International Inc. (NYSE:BAX), a global leader in acute care, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s ST Set used in continuous renal replacement therapy (CRRT). The ST Set is a pre-connected, disposable, extracorporeal (outside the body) circuit that provides blood purification through a semipermeable membrane to be used with the PrisMax or Prismaflex control units (monitors). It has been available to customers in the U.S. since August 2020, when it received Emergency Use Authorization (EUA) from the FDA to provide CRRT to treat patients in an acute care environment during the COVID-19 pandemic. The ST Set is currently in use across countries in Europe, Asia Pacific and North and South America. 

“We are pleased to offer the ST Set to healthcare providers and hospitals in the U.S. on a permanent basis to continue helping them meet the diverse needs of patients treated with CRRT,” said Reaz Rasul, general manager of Baxter’s Acute Therapies business. “The ST Set has played an important role in increasing the availability of CRRT sets, which have been in high demand during the COVID-19 pandemic, and this clearance will help expand access to CRRT for patients with acute kidney injury (AKI).”

AKI is a sudden decrease in kidney function over a period of hours to days, often as a result of illness, trauma or infection. The sudden loss of kidney function leads to the accumulation of toxins and fluid in the blood that, if left untreated, may lead to death. AKI is an increasingly common complication of acute illnesses in intensive care units and hospitals1 2 3 and is one of many complications affecting COVID-19 patients. CRRT mimics many of the functions of the natural kidney and is the cornerstone of treatment in patients with severe AKI.4 During CRRT, the patient’s blood passes through a special filter, such as the ST Set, where fluid and uremic toxins are removed before the cleaned blood is returned to the body.

The ST Set includes three sizes (ST60, ST100 and ST150) that allow the healthcare provider to choose the most appropriate option for the patient. It features Baxter’s proprietary AN69 membrane, which can adsorb toxins with basic residues on the surface by means of ionic interactions. The ST Set works with all CRRT modalities and most commonly used anti-coagulants. 

About Baxter 
Every day, millions of patients, caregivers and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

Rx Only. For safe and proper use of these devices, including contraindications, refer to the full Instructions for Use. 

Important Safety Information 
The Prismaflex ST set is a single use device that provides blood purification through a semipermeable membrane. The Prismaflex ST set is for use only in conjunction with the Prismaflex control unit or with the PrisMax control unit (in countries where PrisMax is cleared or registered). All treatments administered via the Prismaflex ST sets must be prescribed by a physician. The size, weight, state of uremia, cardiac status, and general physical condition of the patient must be carefully evaluated by the prescribing physician before each treatment.

If patients suffer from acute kidney injury and / or volume overload, the Prismaflex ST set is indicated for continuous renal replacement therapies (CRRT), in modalities such as:

  • Slow Continuous UltraFiltration (SCUF)
  • Continuous Veno-Venous Hemofiltration (CVVH)
  • Continuous Veno-Venous HemoDialysis (CVVHD) 
  • Continuous Veno-Venous HemoDiaFiltration (CVVHDF)

to perform fluid management and reduction of uremic toxins.
The Prismaflex ST100 set and ST150 is indicated for use in patients with a body weight equal or greater than 30kg (66lb) and Prismaflex ST60 set is indicated to patients with a body weight greater than 11kg (24lb).

This release includes forward-looking statements concerning the ST Set, including potential benefits associated with its use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance for new and existing products; product development risks; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of natural disasters, public health crises and epidemics/pandemics, regulatory actions or otherwise); satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.

Baxter, PrisMax, Prismaflex and AN69 are registered trademarks of Baxter International Inc. 

1 Siew ED, Davenport A: The growth of acute kidney injury: a rising tide or just closer attention to detail? Kidney Int 2015;87:46-61.  

2 O'Connor ME, Kirwan CJ, Pearse RM, Prowle JR: Incidence and associations of acute kidney injury after major abdominal surgery. Intensive Care Med 2016;42:521-530.  

3 Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani F, Koulouridis I, Jaber BL: World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol 2013;8:1482-1493.  

4 Lins RL, Nephrol Dial Transplant.  2012;27:4252-4255